In this therapy, a section of a patient’s tumor is excised and grown in culture in the presence of IL-2 to promote the selection of lymphocytes, which overgrow and destroy the tumor cells within 2–3 weeks [90]. This evidence concerns the gene IL2 and neoplasm.